Acute Repetitive Seizures Market Report 2026

The acute repetitive seizures market size has grown rapidly in recent years. It will grow from $3.5 billion in 2025 to $3.91 billion in 2026 at a compound annual growth rate (CAGR) of 11.6%. The growth in the historic period can be attributed to limited availability of rapid-acting antiepileptic drugs, rising prevalence of epilepsy and neurological disorders, increased hospital-based seizure management, growing adoption of benzodiazepines, expansion of clinical guidelines for acute seizure treatment.

The acute repetitive seizures market size is expected to see rapid growth in the next few years. It will grow to $5.99 billion in 2030 at a compound annual growth rate (CAGR) of 11.3%. The growth in the forecast period can be attributed to development of intranasal and rectal formulations, increasing focus on home-based seizure management, rising adoption of novel antiepileptic drugs, integration of digital seizure monitoring devices, growth in personalized and precision neurology therapies. Major trends in the forecast period include rising adoption of intranasal and rectal drug delivery methods, increasing use of benzodiazepines for acute seizure management, expansion of home care and ambulatory care settings, growing awareness of rapid intervention protocols, advancements in personalized epilepsy treatment.

The rising prevalence of neurological disorders is expected to propel the growth of the acute repetitive seizures market going forward. Neurological disorders are health conditions that affect the brain, nerves, or spinal cord, causing problems with movement, speech, thinking, or body functions. The rising prevalence of neurological disorders is primarily due to an aging population, as older adults are more susceptible to degenerative brain changes, increasing the risk of conditions like Alzheimer's disease, Parkinson's disease, and stroke. Acute repetitive seizures contribute to the progression of neurological disorders by increasing the risk of neuronal damage, cognitive decline, and long-term complications, necessitating early intervention to prevent worsening outcomes. For instance, in March 2023, according to the Alzheimer's Association, a US-based nonprofit voluntary health organization, approximately 6.7 million Americans aged 65 and older are living with Alzheimer's dementia, which is projected to rise to 13.8 million by 2060. Therefore, the rising prevalence of neurological disorders is driving the growth of the acute repetitive seizures market.

Major companies operating in the acute repetitive seizures market are focusing on developing innovative formulations such as benzodiazepine buccal film to improve drug absorption, provide rapid seizure relief, and enhance patient convenience. Benzodiazepine buccal film is a thin, dissolvable film containing a benzodiazepine medication placed inside the cheek for rapid absorption through the oral mucosa. It helps manage acute repetitive seizures by delivering the drug quickly into the bloodstream, reducing seizure duration and frequency. For instance, in December 2024, Aquestive Therapeutics Inc., a US-based pharmaceutical company, announced that its product, Libervant (diazepam) buccal film, received seven years of orphan drug exclusivity (ODE) from the U.S. Food and Drug Administration (FDA). Libervant is used for the acute treatment of intermittent, stereotypic episodes of frequent seizures, including seizure clusters and acute repetitive seizures. It is a buccally administered dissolvable film of diazepam. This benzodiazepine enhances the effects of gamma-aminobutyric acid (GABA) to reduce seizure activity by acting as a central nervous system depressant.

In March 2023, Pharmanovia, a UK-based lifecycle management company, expanded its exclusive license and supply agreement with Aquestive Therapeutics, Inc., for Libervant (diazepam) buccal film to cover additional global markets outside the US, Canada, and China. Under the expanded collaboration, Pharmanovia will lead regulatory and commercialization efforts in the licensed territories, while Aquestive will continue as the exclusive manufacturer and supplier. Aquestive Therapeutics is a US-based company that provides a treatment for acute repetitive seizures.

Major companies operating in the acute repetitive seizures market are Pfizer Inc., Sanofi S.A., Novartis AG, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Boehringer Ingelheim International GmbH, Bausch Health US LLC., UCB S.A., Eisai Co. Ltd., Sun Pharmaceutical Industries Ltd., Hikma Pharmaceuticals PLC, Zydus Lifesciences Limited, Endo International plc, Lupin Limited, Amneal Pharmaceuticals LLC, Aquestive Therapeutics Inc., Neurelis Inc., Grupo Ferrer Internacional S.A., UpsherSmith Laboratories LLC, Aculys Pharma Inc.

North America was the largest region in the acute repetitive seizures market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the acute repetitive seizures market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the acute repetitive seizures market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have impacted the acute repetitive seizures market by increasing the cost of imported active pharmaceutical ingredients, specialized drug formulations, and delivery devices. Segments such as intranasal and rectal drug delivery systems are most affected, with regions like north america, europe, and asia-pacific experiencing higher procurement costs. These tariffs have led to supply chain adjustments and elevated treatment expenses. On the positive side, tariffs are encouraging local production of seizure management drugs and fostering investment in domestic formulation technologies.

The acute repetitive seizures market research report is one of a series of new reports that provides acute repetitive seizures market statistics, including acute repetitive seizures industry global market size, regional shares, competitors with a acute repetitive seizures market share, detailed acute repetitive seizures market segments, market trends and opportunities, and any further data you may need to thrive in the acute repetitive seizures industry. This acute repetitive seizures market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Acute repetitive seizures refer to a condition in which a person experiences multiple seizures within a short period, typically occurring within 24 hours. These seizures happen repeatedly, often without a return to normal consciousness or baseline neurological function between episodes. They can be triggered by factors such as brain injury, infections, metabolic disturbances, or underlying neurological disorders.

The main drug types used to treat acute repetitive seizures include benzodiazepines, antiepileptic drugs, barbiturates, and other medications. Benzodiazepines are fast-acting drugs that calm excessive brain activity to stop acute seizures and prevent status epilepticus. These medications are administered through various routes, including intranasal, rectal, oral, and others, and are used by end users such as hospitals, clinics, and home care settings.

The acute repetitive seizures market consists of revenues earned by entities by providing services such as emergency medical services, hospital-based treatment, telemedicine and remote monitoring, specialty pharmacy services, seizure action plan development. The market value includes the value of related goods sold by the service provider or included within the service offering. The acute repetitive seizures market also includes sales of intranasal rescue medications, rectal diazepam gel, anticonvulsants, and wearable seizure detection devices. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.